Progression, Remission and Regression of Chronic Renal Diseases
- PMID: 27096936
- DOI: 10.1159/000445844
Progression, Remission and Regression of Chronic Renal Diseases
Abstract
Progression to end-stage renal disease is common in chronic nephropathies, independent of the initial insult. While genetic factors may contribute to susceptibility and progression of renal disease, proteinuria has been documented as an independent predictor of outcome. Reduction of urinary protein levels by restoration of glomerular sieving function with renin-angiotensin system (RAS) blockers has been shown to limit renal function decline in individuals with non-diabetic and diabetic nephropathies to the point that remission of the disease and regression of renal lesions have been observed in experimental animals and even in humans. In animal models, regression of glomerular structural changes is associated with remodeling of glomerular architecture. This review briefly describes our understanding of the mechanism of renal disease progression, the therapeutic advantages of ameliorating glomerular sieving dysfunction and proteinuria of RAS inhibitors and how remission/regression of renal injury can be achieved with multifactorial interventions.
© 2016 S. Karger AG, Basel.
Similar articles
-
Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition.Ann Intern Med. 2002 Apr 16;136(8):604-15. doi: 10.7326/0003-4819-136-8-200204160-00010. Ann Intern Med. 2002. PMID: 11955029 Review.
-
Targeting the renin angiotensin system for remission/regression of chronic kidney disease.Histol Histopathol. 2010 May;25(5):655-68. doi: 10.14670/HH-25.655. Histol Histopathol. 2010. PMID: 20238303 Review.
-
The Remission Clinic approach to halt the progression of kidney disease.J Nephrol. 2011 May-Jun;24(3):274-81. doi: 10.5301/JN.2011.7763. J Nephrol. 2011. PMID: 21534237
-
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].Presse Med. 2002 Nov 9;31(36):1714-20. Presse Med. 2002. PMID: 12467154 Review. French.
-
Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?Minerva Med. 2004 Oct;95(5):395-409. Minerva Med. 2004. PMID: 15467515 Review.
Cited by
-
Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.Kidney Blood Press Res. 2018;43(2):329-349. doi: 10.1159/000487902. Epub 2018 Mar 6. Kidney Blood Press Res. 2018. PMID: 29529602 Free PMC article.
-
Trajectories of kidney function and risk of mortality.Int J Epidemiol. 2023 Dec 25;52(6):1959-1967. doi: 10.1093/ije/dyad111. Int J Epidemiol. 2023. PMID: 37649343 Free PMC article.
-
Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia.Sci Rep. 2025 Mar 15;15(1):8990. doi: 10.1038/s41598-025-94020-2. Sci Rep. 2025. PMID: 40089552 Free PMC article.
-
Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis.Front Pharmacol. 2018 Oct 17;9:1195. doi: 10.3389/fphar.2018.01195. eCollection 2018. Front Pharmacol. 2018. PMID: 30386246 Free PMC article.
-
Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients.BMC Nephrol. 2017 Jul 6;18(1):219. doi: 10.1186/s12882-017-0625-3. BMC Nephrol. 2017. PMID: 28683789 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical